Atopic Dermatitis | Pfizer | B7451050
Pharmaceutical Company/Sponsor:
Pfizer
Code:
B7451050
Title:
A PHASE 3B RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED MULTI-CENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Type:
Interventional
Phase:
3
Condition/Disease:
Atopic Dermatitis
Intervention(s)/Treatment(s):
Drug: Abrocitinib 200 mg
Combination Product: Dupilumab 300 mg
Status:
Recruiting
Link for Additional Information:
